Congress funds study to close HPV testing gap for men
H.R. 8939 — Closing the HPV Testing Gap Act · Filed by LaMonica McIver (D-NJ) · 20 cosponsors · Introduced May 20, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill directs the National Institutes of Health to study how to develop and test for HPV (human papillomavirus) in men, a gap that currently exists since no FDA-approved HPV diagnostic test for men is available. The study will examine noninvasive testing methods, assess feasibility across diverse populations, and recommend regulatory pathways for approval and equitable access, with a final report due within 30 months.
Why we flagged it
The bill is a straightforward research directive with no regulatory or commercial carve-outs. It funds NIH to study a documented public health gap and report findings to Congress—a standard evidence-gathering mechanism for policy development.
What the text implies
- Successful development of an HPV test for men could eventually lead to routine screening recommendations, creating ongoing demand for testing infrastructure and potentially affecting clinical laboratory capacity and reimbursement models.
- The study's focus on 'diverse populations' and 'underserved communities' may surface disparities in HPV prevalence and cancer risk among men, potentially informing future targeted public health interventions.
The full analysis lists 3 implications of this text.
Who stands to gain
diagnostic test manufacturers (future); clinical laboratories; research institutions conducting pilot studies